Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

1,500 volunteers tracked to uncover hidden throat cancer clues

NCT ID NCT03644563

Knowledge-focused Sponsor: Johns Hopkins University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study is screening 1,500 adults for oral HPV infection and antibodies to build a group at higher risk for HPV-related throat cancer. Researchers will follow them over time to see which infections persist and what factors (like mouth bacteria or immune response) increase cancer risk. No treatment is given—the goal is to learn how to predict and possibly prevent this cancer in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help identify who is at highest risk for HPV-related throat cancer, leading to better screening or prevention strategies.
What could go wrong
This is an observational study, not a treatment trial. It may not lead to any direct medical benefit, and results may take years to translate into practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2017

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Target sample size: 1325 (phase 1), \~250 (phase 2) Inclusion of women and minorities: Primary enrollment is restricted to men, given their higher risk of infection (see eligibility criteria). However, the investigators expect to enroll women with cervical dysplasia and partners of patients with HPV-related cancer (\~125 expected women enrollees). Enrollment is across many different sources (geographically, and by clinic type), and is inclusive of diverse racial and ethnic backgrounds. Enrollment is not stratified by race but the investigators expect to enroll at least 175 minorities in the study.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Participants in the Phase 1 Screening Inclusion criteria: In order to be eligible to participate in this study, an individual must meet all of the following criteria: * 18 and older (enrollment at most sites will be restricted to 30 and older since this demographic has the highest prevalence of infection; however, individuals and/or partners of someone with an HPV-related cancer, for example, are at increased risk so will be enrolled in the larger age range). * Willing to be contacted to arrange follow-up visits, if determined to be eligible for phase 2 * Ability to understand and the willingness to sign a written informed consent document In addition, individuals must meet at least one of the following criteria: * Male, aged 30 and older, with 2 or more lifetime oral sex * History of anal or genital dysplasia or cancer * Partners of someone with an HPV-related cancer (HPV-positive OPC, anal cancer or genital cancer) * Known oncogenic HPV-positive biomarker from prior studies or testing, regardless of number of partners. Exclusion criteria: An individual who meets any of the following criteria will be excluded from participation in this study: * Presence of medical or psychiatric condition affecting ability to give voluntary, informed consent. * Participants who do not speak English cannot enroll because the consent and study survey are only available in English. However, if there is a hearing, literacy or minor fluency issue and the participant requests assistance from a family member or the study coordinator, this individual may still enroll and receive this assistance to ensure they fully hear and understand everything being asked. * History of head and neck cancer Participants in the Phase 2 Follow-Up Inclusion criteria: * Oncogenic oral HPV infection and/or HPV serum oncogenic antibodies detected in phase 1 * Willingness to complete annual follow up visits Exclusion criteria: • Unable to complete annual follow up visits

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Human papilloma virus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

human papilloma virus infection oropharyngeal carcinoma oropharynx cancer Persistent Infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Human papilloma virus Oropharyngeal cancer

Contacts and locations

Locations

  • Johns Hopkins Hospital

    Baltimore, Maryland, 21205, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.